Teva and Nuvelution Pharma partner to accelerate development of AUSTEDO®
Teva and Nuvelution Pharma announced a partnership to develop AUSTEDO® (deutetrabenazine) tablets for treatment of tics associated with Tourette syndrome in pediatric patients in the U.S. Upon FDA approval of AUSTEDO® in TS, Teva will pay Nuvelution a pre-agreed return on its invested capital. September 19, 2017